The lead’s diameter is 4.7 Fr, or 1.6 mm, roughly equal to graphite in a wooden pencil.

The FDA approved OmniaSecure early last year for right ventricle placement to treat ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias in adults and pediatric patients ages 12 and up.

Medtronic engineered OmniaSecure from its Medtronic SelectSecure Model 3830 pacing lead, which the company says has delivered safe and reliable therapy to patients for more than 20 years.

The first cases are now taking place at hospitals across the United States.